Preclinical studies of immunomicelles incorporating anticancer drugs

Abstract

Selective tumor targeting of therapeutic agents is a longstanding pharmacological goal to improve a therapeutic index. Most scientists have sought to use active receptor-mediated tumor-targeting systems, however the passive targeting afforded by the enhanced permeability and retention （EPR）effect provides a versatile and non-saturable opportunity for tumor-selective delivery. In this context, collaborating with NanoCarrier Co., Ltd., we succeeded in constructing anti-tissue factor （TF）antibody-conjugated micelles incorporating anticancer drugs. In this review article, Drug Delivery System （DDS）of passive and active targeting is described and immunomicelle possessing both passive and active targeting ability is discussed in more detail.